Primary liver cancer and metastatic liver cancer are common malignant tumors in clinical practice, and their treatment is mainly surgical resection. However, most patients with hepatocellular carcinoma have lost the opportunity of surgery due to poor general condition and late stage of the disease when they are found. Transcatheter Arterial Chemoembolization (TACE) is a non-surgical tumor treatment method developed in the 1980s, which has good efficacy on liver cancer and is even recommended as the first choice of non-surgical treatment. It can shrink the tumor and give some patients the opportunity to receive surgery. It can also prolong survival for patients with intermediate to advanced disease, while greatly improving quality of life. The liver has dual blood supply from hepatic artery and portal vein, and hepatic artery is the main blood supply route for hepatocellular carcinoma. On the one hand, through direct chemotherapy, the first drug can pass through the tumor, which results in higher local drug concentration and stronger effect on killing tumor cells; on the other hand, the hepatic artery is embolized, which leads to ischemia and necrosis of tumor tissues, thus hepatic artery chemoembolization is a very effective method to control tumor and reduce tumor volume. Therefore, hepatic artery chemoembolization is a very effective method to control tumor and reduce tumor size. The specific method is to insert the catheter through the femoral artery directly to the hepatic artery or its branches under the guidance of X ray, and the microcatheter is super-selected to the tumor blood supply artery, and the imaging shows the tumor staining, and then the chemotherapeutic drug is injected through the catheter, and then the embolic agent (such as iodized oil, gelatin sponge, etc.) is injected through the catheter to block the hepatic artery blood supply of the cancer nodule. blocked. Sometimes, chemical anticancer drugs such as adriamycin, mitomycin, cis-chloramphenicol, etc. are mixed with embolic agent, and then this suspension is injected into the hepatic artery. The embolic agent in the suspension can stay in the liver tissue for a long time, and the chemotherapeutic drugs in it are also released slowly in the cancer tissue, so that it can play a long time anticancer effect, and the toxic reaction of chemotherapeutic drugs to the normal tissues of the body can be significantly reduced. Hepatic artery embolization chemotherapy is currently the preferred method of non-surgical treatment due to its good efficacy and low adverse effects, but it has certain application limits. For patients with tumor volume exceeding 2/3 of liver volume, portal vein thrombosis, severe portal hypertension, and patients with severe cardiac, hepatic and renal insufficiency or coagulation dysfunction and low white blood cells (<3?5×109/L), hepatic artery embolization chemotherapy is not suitable. The commonly used drugs for hepatic artery embolization chemotherapy are CDDP, 5Fu, mitomycin [or adriamycin]. The chemotherapy regimens used in TACE treatment of hepatocellular carcinoma vary widely throughout the world. In China, high-dose combination chemotherapy is often reported, but in Europe and the United States, single-agent chemotherapy is usually used, and in Japan, low-dose chemotherapy is usually used; some scholars even believe that embolization plays a major role in TACE, and chemotherapy drugs play little role. Hepatic artery embolization chemotherapy can also be combined with radiofrequency ablation (RFA), argon helium knife freezing, anhydrous ethanol ablation (PEI) and other methods to further improve the therapeutic effect. As a tumor with high malignancy, recurrence rate and mortality, the treatment of hepatocellular carcinoma also requires the integrated application of multiple therapeutic tools.